In 2016 the number of individuals that suffer from the degenerative brain disease Parkinson’s hit 6.1 million. In 1990 the total was 2.5 million, marking an alarming rise of almost 150% in just over 25 years. While the global population has risen over that period, explaining part of the rise in numbers affected by Parkinson’s Disease, its instance has also significantly increased.
Currently, one in 350 Brits suffers from the disease but Parkinson’s UK research forecasts that to rise by almost 18% by 2025. The rise in numbers of Parkinson’s sufferers is put mainly down an older population more often surviving other conditions that would have, in the past, killed them off before the onset of the disease, which is most commonly found in the over-50s.
However, the latest biotechnology breakthroughs are providing hope for many sufferers with leading researchers confident that the ‘key’ to a Parkinson’s cure is as little as five years away. Several clinical trials launched this year, with more to come in 2019. While it is unlikely a single medication will provide the silver bullet for curing Parkinson’s, specialists believe that it is highly likely that some of the clinical trials ongoing and due to commence will bear fruit. It is believed that new biotech-based treatments targeting different symptoms of the disease, which include tremors, muscle stiffness, problems with balance and depression and anxiety, will combine to provide an effective cure.
Parkinson’s symptoms are caused by a gradual dying off of brain cells leading to a loss of dopamine, the biological chemical vital to our control of movement. While not directly fatal, Parkinson’s…